aTyr Pharma, Inc. Q2 FY2022 earnings call

• Progressed the Phase 3 study of efzofitimod in pulmonary sarcoidosis, with plans to enroll patients this quarter, multiple regulatory interactions completed, and site initiation for the study.
• EFZO-FIT is a global pivotal Phase 3 study with a primary endpoint of steroid reduction, and it's designed to evaluate efficacy and safety of efzofitimod.
• Received FDA Fast Track Designation for efzofitimod for pulmonary sarcoidosis, facilitating development and review.
• 2810 preclinical program aims to initiate a Phase 1 study in Q4 2022, targeting specific aggressive solid tumors.
• Ended Q2 2022 with $89.3 million in cash, R&D expenses $9.1 million, and G&A expenses $3.4 million.

There is no traditional product segment financial performance detailed in the transcript. The company focuses on clinical and preclinical programs, with efforts centered on the efzofitimod clinical program and the 2810 preclinical program.

• Timeline for data release from the EFZO-FIT study is approximately 2-2.5 years from enrollment, and guidance may be updated based on enrollment progress.
• The company expects to follow the initial timeline assumptions depending on enrollment progress.

• Operational challenges in enrolling patients and mobilizing sites for the EFZO-FIT study.
• Regulatory uncertainties in gaining approvals for efzofitimod and 2810.
• Uncertainties around the timeline for clinical trial results and their impact on market potential.

Q: Gregory Renza asked about regulatory alignment in ex-US countries and operational challenges in enrolling patients.

A: Sanjay responded that regulatory interactions have been productive, primary endpoint agreement is strong, and the operational team is efficient in mobilizing sites.

Q: Joe Pantginis asked about exclusion criteria, imaging, and 2810 Phase 1 study.

A: Sanjay discussed using imaging to exclude overly fibrotic patients and plans for 2810 Phase 1 including target tumor type selection.

Q: Hartaj Singh asked about taper in EFZO-FIT study and differences in developing oncology vs. inflammation therapies.

A: Sanjay talked about the taper design aiding enrollment and regulatory interactions being easier for oncology programs due to biology understanding.

Q: Yale Jen asked about EFZO-FIT timeline, mixed patients, and 2810 Phase 1 study.

A: Sanjay discussed timeline expectations, analyzing mixed patients for potential expanded indications, and 2810 Phase 1 design with adaptive approach